


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199181</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1942-0870</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>mAbs</Title>
                <ISOAbbreviation>MAbs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Engineering an anti-CD52 antibody for enhanced deamidation stability.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/19420862.2019.1631117</ELocationID>
            <Abstract>
                <AbstractText>Deamidation evaluation and mitigation is an important aspect of therapeutic antibody developability assessment. We investigated the structure and function of the Asn-Gly deamidation in a human anti-CD52 IgG1 antibody light chain complementarity-determining region 1, and risk mitigation through protein engineering. Antigen binding affinity was found to decrease about 400-fold when Asn<sup>33</sup> was replaced with an Asp residue to mimic the deamidation product, suggesting significant impacts on antibody function. Other variants made at Asn<sup>33</sup> (N33H, N33Q, N33H, N33R) were also found to result in significant loss of antigen binding affinity. The co-crystal structure of the antigen-binding fragment bound to a CD52 peptide mimetic was solved at 2.2Ã… (PDB code 6OBD), which revealed that Asn<sup>33</sup> directly interacts with the CD52 phosphate group via a hydrogen bond. Gly<sup>34</sup>, but sits away from the binding interface, rendering it more amendable to mutagenesis without affecting affinity. Saturation mutants at Gly<sup>34</sup> were prepared and subjected to forced deamidation by incubation at elevated pH and temperature. Three mutants (G34R, G34K and G34Q) showed increased resistance to deamidation by LC-MS peptide mapping, while maintaining high binding affinity to CD52 antigen measured by Biacore. A complement -dependent cytotoxicity assay indicated that these mutants function by triggering antibody effector function. This study illustrates the importance of structure-based design and extensive mutagenesis to mitigate antibody developability issues.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Huawei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Biologics Research , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Ronnie</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3606-6055</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Biologics Research , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jaworski</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0633-287X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Biologics Research , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boudanova</LastName>
                    <ForeName>Ekaterina</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Biologics Research , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hughes</LastName>
                    <ForeName>Heather</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Biologics Development , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>VanPatten</LastName>
                    <ForeName>Scott</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Biologics Development , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lund</LastName>
                    <ForeName>Anders</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Biologics Development , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Day</LastName>
                    <ForeName>Jaime</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-1969-2647</Identifier>
                    <AffiliationInfo>
                        <Affiliation>b Biologics Development , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Yanfeng</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>a Biologics Research , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McSherry</LastName>
                    <ForeName>Tracey</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8198-5870</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Biologics Research , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pan</LastName>
                    <ForeName>Clark Q</ForeName>
                    <Initials>CQ</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5110-1803</Identifier>
                    <AffiliationInfo>
                        <Affiliation>a Biologics Research , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sendak</LastName>
                    <ForeName>Rebecca</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Biologics Development , Sanofi, 49 New York Ave, Framingham , MA 01701 , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>MAbs</MedlineTA>
            <NlmUniqueID>101479829</NlmUniqueID>
            <ISSNLinking>1942-0862</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antibody engineering</Keyword>
            <Keyword MajorTopicYN="N">deamidation</Keyword>
            <Keyword MajorTopicYN="N">developability</Keyword>
            <Keyword MajorTopicYN="N">mutagenesis</Keyword>
            <Keyword MajorTopicYN="N">structure-function</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199181</ArticleId>
            <ArticleId IdType="doi">10.1080/19420862.2019.1631117</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

